Low impact
Pfizer-partnered Hangzhou Sciwind Biosciences is in deep discussions to expand its obesity drug beyond China, citing clinical data showing superior weight loss vs. Novo's Wegovy.
BLOOMBERG06/08, 05:01 AM
Related assets
Coming up for NVO
Explore next
Latest NVO news
MarketWatch08/27, 03:37 PM
Deutsche Bank downgraded Novo Nordisk to sell after the stock fell 70% from its peak.
Jin1008/27, 10:33 AM
Novo Nordisk has applied for approval of an oral formulation of Wegovy for weight management.
Finnhub08/19, 05:10 PM